They could do it on their own if they chose. Biodel did. The real expensive cost and risk would be in distribution and marketing not to mention commercial supply, various device injectors and so forth. So its unlikely and would be a bad sign if they didn't license out pre phase III. LLY, Sanofi and Novo Nordisk are the 3 primary possibilities.
Market Data 
Markets 
AI
